EE05150B1 - Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod - Google Patents

Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod

Info

Publication number
EE05150B1
EE05150B1 EEP200100430A EEP200100430A EE05150B1 EE 05150 B1 EE05150 B1 EE 05150B1 EE P200100430 A EEP200100430 A EE P200100430A EE P200100430 A EEP200100430 A EE P200100430A EE 05150 B1 EE05150 B1 EE 05150B1
Authority
EE
Estonia
Prior art keywords
methylsulfone
vin
fluorophenyl
pyrimidine
dioxane
Prior art date
Application number
EEP200100430A
Other languages
English (en)
Estonian (et)
Inventor
Philip Taylor Nigel
Koike Haruo
Kabaki Mikio
Joseph Diorazio Louis
Original Assignee
Astrazeneca Ab
Shionogi & Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05150(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Shionogi & Co. Ltd. filed Critical Astrazeneca Ab
Priority to EEP200900043A priority Critical patent/EE05531B1/xx
Publication of EE200100430A publication Critical patent/EE200100430A/xx
Publication of EE05150B1 publication Critical patent/EE05150B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200100430A 1999-02-17 2000-02-15 Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod EE05150B1 (et)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EEP200900043A EE05531B1 (et) 1999-02-17 2000-02-15 Tert-butl-(E)-(6-{2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]vinl}(4R, 6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903472.0A GB9903472D0 (en) 1999-02-17 1999-02-17 Chemical process
PCT/GB2000/000481 WO2000049014A1 (en) 1999-02-17 2000-02-15 Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate

Publications (2)

Publication Number Publication Date
EE200100430A EE200100430A (et) 2002-12-16
EE05150B1 true EE05150B1 (et) 2009-04-15

Family

ID=10847843

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200900043A EE05531B1 (et) 1999-02-17 2000-02-15 Tert-butl-(E)-(6-{2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]vinl}(4R, 6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod
EEP200100430A EE05150B1 (et) 1999-02-17 2000-02-15 Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EEP200900043A EE05531B1 (et) 1999-02-17 2000-02-15 Tert-butl-(E)-(6-{2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]vinl}(4R, 6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod

Country Status (34)

Country Link
US (2) US6844437B1 (tr)
EP (1) EP1155015B1 (tr)
JP (3) JP2003518474A (tr)
KR (1) KR100648160B1 (tr)
CN (1) CN1145625C (tr)
AR (1) AR022600A1 (tr)
AT (1) ATE415398T1 (tr)
AU (1) AU760145B2 (tr)
BR (1) BRPI0008301B8 (tr)
CA (1) CA2362594C (tr)
CL (1) CL2003002336A1 (tr)
CY (1) CY1108733T1 (tr)
CZ (1) CZ299844B6 (tr)
DE (1) DE60040905D1 (tr)
DK (1) DK1155015T3 (tr)
EE (2) EE05531B1 (tr)
ES (1) ES2316349T3 (tr)
GB (1) GB9903472D0 (tr)
HK (1) HK1041265B (tr)
HU (1) HU229835B1 (tr)
IL (2) IL144793A0 (tr)
IS (1) IS2711B (tr)
MX (1) MXPA01008235A (tr)
NO (1) NO320739B1 (tr)
NZ (1) NZ513261A (tr)
PL (1) PL218518B1 (tr)
PT (1) PT1155015E (tr)
RU (1) RU2243969C2 (tr)
SI (1) SI1155015T1 (tr)
SK (1) SK286988B6 (tr)
TR (2) TR200401874T2 (tr)
TW (1) TWI285202B (tr)
WO (1) WO2000049014A1 (tr)
ZA (1) ZA200106370B (tr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902202D0 (sv) * 1999-06-10 1999-06-10 Astra Ab Production of aggregates
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) * 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
RU2301801C2 (ru) * 2001-07-13 2007-06-27 АстраЗенека Ю-Кей Лимитед Способ получения сульфониламинопиримидиновых соединений (варианты), промежуточные продукты и способы их получения
HRPK20040255B3 (en) * 2001-08-16 2006-02-28 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
EP1323717A1 (en) * 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ES2335279T3 (es) 2002-12-16 2010-03-24 Astrazeneca Uk Limited Procedimiento para la preparacion de compuestos de pirimidina.
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) * 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
GB0406757D0 (en) 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
WO2006017357A1 (en) 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
GB0427491D0 (en) 2004-12-16 2005-01-19 Avecia Ltd Process and compounds
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CN100351240C (zh) * 2005-01-19 2007-11-28 安徽省庆云医药化工有限公司 瑞舒伐他汀钙的合成方法
KR101020024B1 (ko) 2005-02-22 2011-03-09 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법
WO2006100689A1 (en) * 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
WO2006106526A1 (en) * 2005-04-04 2006-10-12 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
HU227120B1 (hu) * 2005-05-26 2010-07-28 Richter Gedeon Nyrt Eljárás rosuvastatin kalciumsójának elõállítására új intermediereken keresztül
WO2006136408A2 (en) * 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing pure amorphous rosuvastatin calcium
US9150518B2 (en) * 2005-06-24 2015-10-06 Lek Pharmaceuticals, D.D. Process for preparing amorphous rosuvastatin calcium of impurities
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
WO2007017117A1 (en) * 2005-07-28 2007-02-15 Lek Pharmaceuticals D.D. Process for the synthesis of rosuvastatin calcium
WO2007022488A2 (en) 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
CN100436428C (zh) * 2005-08-22 2008-11-26 鲁南制药集团股份有限公司 瑞舒伐他汀及其盐的制备方法
CN100352821C (zh) * 2005-08-22 2007-12-05 鲁南制药集团股份有限公司 一种瑞舒伐他汀钙中间体的制备方法
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) * 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8318933B2 (en) 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
WO2008072078A1 (en) 2006-12-13 2008-06-19 Aurobindo Pharma Limited An improved process for preparing rosuvastatin caclium
ES2385623T3 (es) 2007-02-08 2012-07-27 Aurobindo Pharma Limited Un procedimiento mejorado para la preparación de rosuvastatina cálcica
US7687660B2 (en) 2007-04-18 2010-03-30 Teva Pharmaceutical Industries Ltd. Process for preparing intermediates of HMG-CoA reductase inhibitors
US20090069563A1 (en) 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
EP2181089A2 (en) 2007-08-28 2010-05-05 Ratiopharm GmbH Process for preparing pentanoic diacid derivatives
CN101376647B (zh) * 2007-08-31 2010-12-08 中山奕安泰医药科技有限公司 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
PT2309992T (pt) 2008-06-27 2018-01-22 Krka Tovarna Zdravil D D Novo Mesto Composição farmacêutica compreendendo uma estatina
WO2010029561A1 (en) * 2008-09-09 2010-03-18 Biocon Limited A process for preparation of rosuvastatin acetonide calcium
EP2350025A1 (en) * 2008-09-30 2011-08-03 Aurobindo Pharma Limited An improved process for preparing pyrimidine propenaldehyde
EP2351762B1 (en) * 2008-10-20 2013-10-16 Kaneka Corporation NOVEL PYRIMIDINE DERIVATIVE AND METHOD FOR PRODUCING HMG-CoA REDUCTASE INHIBITOR INTERMEDIATE
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
KR20100080432A (ko) * 2008-12-29 2010-07-08 한미약품 주식회사 스타틴 화합물의 신규 제조방법 및 이에 사용되는 벤조티아졸릴 술폰 화합물
EP2752407B1 (en) 2009-01-14 2015-09-23 Krka Tovarna Zdravil, D.D., Novo Mesto Crystalline rosuvastatin calcium trihydrate
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
KR101157314B1 (ko) 2009-06-05 2012-06-15 주식회사종근당 로수바스타틴의 신규한 제조방법, 이 제조에 유용한 중간체 화합물 및 그의 제조방법
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
WO2011104725A2 (en) 2010-02-23 2011-09-01 Cadila Healthcare Limited Hmg-coa reductase inhibitors and process for the preparation thereof
WO2012011129A2 (en) * 2010-07-22 2012-01-26 Msn Laboratories Limited Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
WO2012073256A1 (en) 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
US8865900B2 (en) 2011-01-18 2014-10-21 Dsm Sinochem Pharmaceuticals Netherlands B.V. Methyltetrazole sulfides and sulfones
WO2012098048A1 (en) 2011-01-18 2012-07-26 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of diol sulfones
MX357470B (es) 2011-01-18 2018-07-11 Dsm Sinochem Pharm Nl Bv Procedimiento para la preparación de estatinas en presencia de base.
WO2012172564A1 (en) * 2011-05-25 2012-12-20 Dr. Reddy's Laboratories Limited Process for preparation of rosuvastatin calcium
MX359424B (es) 2011-12-09 2018-09-12 Dsm Sinochem Pharm Nl Bv Proceso para la preparación de un precursor de estatina.
SI2788341T1 (sl) 2011-12-09 2017-06-30 Dsm Sinochem Pharmaceuticals Netherlands B.V. Postopek za pripravo tioprekurzorja za statine
KR20130087153A (ko) * 2012-01-27 2013-08-06 코오롱생명과학 주식회사 로수바스타틴의 제조방법 및 이에 사용되는 중간체 화합물
CN103232398B (zh) * 2012-04-28 2016-04-06 上海科州药物研发有限公司 一种瑞舒伐他汀氨基酸盐及其制备方法和应用
KR101292743B1 (ko) * 2012-05-17 2013-08-02 (주) 에프엔지리서치 신규한 스타틴 중간체 및 이를 이용한 피타바스타틴, 로수바스타틴, 세리바스타틴 및 플루바스타틴의 제조 방법
CN103864697A (zh) * 2012-12-11 2014-06-18 润泽制药(苏州)有限公司 瑞舒伐中间体主链醇的制备方法
WO2014108795A2 (en) 2013-01-10 2014-07-17 Aurobindo Pharma Limited An improved process for the preparation of chiral diol sulfones and statins
CN103420919B (zh) * 2013-08-22 2015-07-08 南京欧信医药技术有限公司 一种嘧啶类衍生物的合成方法
WO2015037018A1 (en) * 2013-09-14 2015-03-19 Ind-Swift Laboratories Limited Process for the preparation of rosuvastatin via novel intermediates
PT3115367T (pt) 2014-03-07 2018-01-04 Asymchem Laboratories Fuxin Co Ltd Composto intermediário para preparar rosuvastatina cálcica e método para preparar rosuvastatina cálcica a partir deste
CN103936680B (zh) * 2014-04-18 2016-08-24 润泽制药(苏州)有限公司 瑞舒伐他汀钙已知杂质的制备方法
CN104788387A (zh) * 2015-04-17 2015-07-22 浙江海森药业有限公司 高纯度瑞舒伐他汀钙的制备方法
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
CN105461636A (zh) * 2015-12-30 2016-04-06 安徽美诺华药物化学有限公司 一种瑞舒伐他汀甲酯的合成方法
CN106478518A (zh) * 2016-09-27 2017-03-08 南通常佑药业科技有限公司 一种庚烯酸环戊酯衍生物的制备方法
KR101953575B1 (ko) 2016-10-24 2019-05-24 한양대학교 에리카산학협력단 스타틴계 고지혈증 치료제 합성을 위한 새로운 중간체 합성 및 이를 이용한 로수바스타틴 합성 공정 개발
CN108997324A (zh) * 2018-08-21 2018-12-14 南京欧信医药技术有限公司 瑞舒伐他汀钙中间体的制备方法
CN109651259B (zh) * 2018-12-29 2020-05-19 浙江永太科技股份有限公司 一种瑞舒伐他汀钙关键中间体的纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
JPH06329679A (ja) * 1993-01-20 1994-11-29 Nissan Chem Ind Ltd 光学活性β−アミノアルコキシボラン錯体
FR2741620B1 (fr) * 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
US6260440B1 (en) * 1999-12-17 2001-07-17 Caterpillar Inc. Method and apparatus for shifting ranges in a continuously variable transmission

Also Published As

Publication number Publication date
EE200100430A (et) 2002-12-16
CZ299844B6 (cs) 2008-12-10
ES2316349T3 (es) 2009-04-16
HK1041265B (en) 2009-07-03
BRPI0008301B8 (pt) 2021-05-25
DE60040905D1 (de) 2009-01-08
IL144793A0 (en) 2002-06-30
TR200102360T2 (tr) 2001-12-21
JP2007291113A (ja) 2007-11-08
ATE415398T1 (de) 2008-12-15
IL163375A (en) 2008-12-29
PL350185A1 (en) 2002-11-18
NO20013994D0 (no) 2001-08-16
AR022600A1 (es) 2002-09-04
SK11832001A3 (sk) 2002-01-07
AU760145B2 (en) 2003-05-08
CA2362594A1 (en) 2000-08-24
EE05531B1 (et) 2012-04-16
IS2709B3 (is) 2011-01-15
CY1108733T1 (el) 2014-04-09
EP1155015B1 (en) 2008-11-26
NO320739B1 (no) 2006-01-23
KR100648160B1 (ko) 2006-11-24
JP2008255114A (ja) 2008-10-23
US20040049036A1 (en) 2004-03-11
ZA200106370B (en) 2002-11-04
HU229835B1 (en) 2014-09-29
KR20010102207A (ko) 2001-11-15
NO20013994L (no) 2001-10-16
IS2711B (is) 2011-01-15
JP4130844B2 (ja) 2008-08-06
HUP0200301A3 (en) 2004-03-29
EE200900043A (et) 2010-02-15
CN1145625C (zh) 2004-04-14
GB9903472D0 (en) 1999-04-07
HUP0200301A2 (en) 2002-08-28
HK1041265A1 (en) 2002-07-05
US6784171B2 (en) 2004-08-31
AU2557300A (en) 2000-09-04
SK286988B6 (sk) 2009-08-06
PL218518B1 (pl) 2014-12-31
BR0008301B1 (pt) 2013-01-22
CN1340052A (zh) 2002-03-13
PT1155015E (pt) 2009-01-27
CL2003002336A1 (es) 2005-01-14
US6844437B1 (en) 2005-01-18
DK1155015T3 (da) 2009-03-02
EP1155015A1 (en) 2001-11-21
TWI285202B (en) 2007-08-11
JP2003518474A (ja) 2003-06-10
RU2243969C2 (ru) 2005-01-10
IS6029A (is) 2001-07-31
CA2362594C (en) 2009-06-02
WO2000049014A1 (en) 2000-08-24
NZ513261A (en) 2003-10-31
TR200401874T2 (tr) 2004-10-21
MXPA01008235A (es) 2002-04-24
SI1155015T1 (sl) 2009-04-30
CZ20012930A3 (cs) 2001-11-14
BR0008301A (pt) 2002-01-22

Similar Documents

Publication Publication Date Title
EE05150B1 (et) Tert-butl-(E)-(6-[2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)ami no]primidiin-5-l]vinl](4R,6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod
DK1129088T3 (da) Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben
HUP0101122A3 (en) Process for the preparation of optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl]acetic acid derivatives
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
PT1185274E (pt) Composicoes de farmacos contendo acido (e) - 7- [4-(4-fluorofenil)- 6-isopropil-2-[metil ( metilsulfonil)amino] pirimidin-5-il] (3r,5s) -di-hidroxi-hept-6-enoico e um inibidor, indutor ou substrato da isoenzima p450 3a4
NO20006039D0 (no) Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
AU2002325570A1 (en) New process for the preparation of optically active 2-(6-(substituted alkyl)-1,3-dioxan-4-yl)acetic acid derivatives
WO2003002580A8 (en) 6-`2-(phosphonomethoxy)alkoxy pyrimidine derivatives having antiviral activity
AU4600200A (en) Salts of 2,2-dimethyl-1,3-dioxane intermediates and process for the preparation thereof
EE200100646A (et) Melagatraani peaaegu kristalne vorm
ID26146A (id) Proses untuk cis-1-{2-[4-(6-metoksi-2-fenil-1,2,3,4-tetrahidronaftalen-1-il]fenoksi]etil} pirolidin
DK1095035T3 (da) Fremgangsmåde til fremstilling af 4-(3-pyridinyl)-1H-imidazol og de anvendte mellemprodukter
ITMI991731A0 (it) Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piper idine
NO20001985L (no) FremgangsmÕte for forming av strimmelformede folier
DK1413575T3 (da) Fremgangsmåde til fremstilling af derivater af (1,5-diaryl)pyrazol-3-ylpropansyre
FI942159L (fi) Menetelmä 2-(4-(4-(4-kloori-1-pyratsolyyli)butyyli)-1-piperatsinyyli)pyrimidiinin (lesopitron) valmistamiseksi
DK1456197T3 (da) Piperidin-2,6-dioner, som er substitueret heterocyklisk i 3-stillingen
AU3231500A (en) Process for the preparation of 6-(perfluoroalkyl) uracil compounds from urea compounds
DK0812842T3 (da) Fremgangsmåde til fremstilling af 5-(alkoxymethyl)-2,3-pyridindicarboximidforbindelser
NO20012028D0 (no) Fremgangsmåte for fremstilling av 4-((2',5'-diamino-6'- halogenpyrimidin-4'-yl)amino)-cyclopent-2-enyl-metanoler
DK1104415T3 (da) Fremgangsmåde til fremstilling af 1,3-oxathiolan-nukleosider
DK1200414T3 (da) Fremgangsmåde til fremstilling af substituerede pyrimidiner
IL176734A (en) Method for the preparation of 1 - (6 - methylpyridine - 3 - yl) - 2 - [4 - (methylsulfonyl) phenyl] ethanone

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231